Cue Biopharma Announces CEO Transition
Rhea-AI Summary
Cue Biopharma (Nasdaq: CUE) appointed Lucinda Warren as interim president and chief executive officer, effective March 27, 2026, after Usman Azam stepped down effective March 26, 2026. The board credited Ms. Warren with recent deal execution, including recovery of CUE-401 rights and collaborations with Boehringer Ingelheim and ImmunoScape.
Ms. Warren said she will focus on advancing CUE-401 into the clinic by the second half of 2026; she has 30+ years of global pharma and biotech experience and prior business development leadership at Johnson & Johnson.
Positive
- Interim CEO Lucinda Warren appointed effective March 27, 2026
- Return of worldwide rights for CUE-401 executed
- Collaboration with Boehringer Ingelheim for CUE-501
- Strategic collaboration and license agreement with ImmunoScape
- CUE-401 targeted for clinic entry H2 2026
Negative
- President and CEO Usman Azam stepped down effective March 26, 2026
- Company in executive transition with interim leadership
Key Figures
Market Reality Check
Peers on Argus
CUE fell 5.03% while peers showed a mixed tape: ACET and PYPD down modestly, PDSB and ALXO up slightly, and INKT up 7.6%. With limited peers in momentum scanners and mixed directions, the move appears stock-specific rather than a broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | R&D day announcement | Positive | -5.0% | Announced April 7 virtual R&D Day focused on lead asset CUE-401. |
| Mar 16 | Earnings and updates | Positive | -12.8% | Reported Q4 and 2025 results, collaboration revenue growth, and ImmunoScape deal. |
| Mar 09 | Clinical data preview | Positive | +0.4% | Planned presentation of new in vitro CUE-401 data at WIRM 2026. |
| Feb 17 | Preclinical safety data | Positive | -5.1% | Reported well-tolerated preclinical CUE-401 safety and outlined IND plans. |
| Feb 12 | Executive appointment | Positive | -6.8% | Appointed Lucinda Warren as Chief Financial and Business Officer to help advance CUE-401. |
Recent news, largely positive around CUE-401 and business development, often coincided with negative price reactions, suggesting a pattern of selling into announcements.
Over the last several weeks, Cue Biopharma has focused communications on advancing its lead autoimmune candidate CUE-401 and strengthening partnerships. Preclinical safety data with no adverse events, new in vitro data, and an upcoming R&D Day on April 7, 2026 highlighted pipeline progress. Financial disclosures showed higher collaboration revenue and an ImmunoScape deal, yet shares declined after several of these updates. Today’s CEO transition follows February’s appointment of Lucinda Warren as Chief Financial and Business Officer, extending an ongoing leadership and strategic reshaping.
Regulatory & Risk Context
On March 17, 2026, Cue Biopharma filed an S-3 shelf registration to offer up to $300,000,000 of various securities. The filing includes an at-the-market agreement with Jefferies to sell up to $12,666,282 of common stock with a 3.0% agent fee, is currently noted as not effective, and shows no usage yet. This structure gives the company flexibility to raise capital via future offerings.
Market Pulse Summary
This announcement highlights a leadership shift, with Lucinda Warren moving from financial and business roles into the interim CEO position as Cue Biopharma advances CUE-401 toward the clinic in 2026. Recent SEC filings detailed stronger collaboration revenue, a new ImmunoScape partnership, and a $300,000,000 S-3 shelf plus a proposed reverse split between 1-for-30 and 1-for-50. Investors may watch execution on CUE-401 timelines, future use of the shelf, and board decisions on capital structure.
Key Terms
shelf registration statement regulatory
at-the-market sales agreement financial
reverse stock split financial
form 10-k regulatory
going concern financial
glp toxicology medical
proxy statement regulatory
AI-generated analysis. Not financial advice.
Lucinda Warren Appointed Interim President and Chief Executive Officer – Usman Azam Steps Down
BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, an industry veteran who has served as Cue Biopharma’s chief financial and business officer since February 2026 and previously as Cue Biopharma’s chief business officer from September 2024 until February 2026, has been appointed interim president and chief executive officer (CEO). Usman Azam has stepped down as president and CEO and as a director, effective March 26, 2026.
“The board of directors thanks Usman for his services to Cue,” said Pasha Sarraf, M.D., Ph.D., chairman of the board of Cue Biopharma. “Furthermore, we are delighted that Lucinda has accepted to step into the president and CEO role during this transition period. Lucinda has successfully executed multiple valuable deals for the Company in the past year, including the return of worldwide development and commercialization rights for CUE-401, our collaboration with Boehringer Ingelheim for CUE-501, and our strategic collaboration and license agreement with ImmunoScape to develop a breakthrough cell therapy for solid tumors. The board is fully supportive and behind Lucinda in her new role, as Cue progresses CUE-401 toward the clinic, and as we continue to pursue creative deals to build value for our shareholders.”
Ms. Warren, added, “I’m honored and committed to lead Cue Biopharma at this time, focused on continuing to drive our key priority of moving CUE-401 into the clinic by the second half of this year.”
Ms. Warren has over 30 years of global experience in the pharmaceutical and biotechnology sectors. Prior to joining Cue Biopharma, she served as vice president of business development for Neuroscience and Japan Regionally at Johnson & Johnson, a healthcare products company, where she was responsible for end-to-end business development, including licensing, mergers and acquisitions, and alliance management. Her leadership was instrumental in optimizing resources, fostering high-performing teams, and cultivating strong relationships with stakeholders. Ms. Warren’s extensive experience also includes significant roles at Janssen Cilag Australia and Janssen Biologics, where she led business units and managed global transitions, consistently delivering value through strategic transactions. She currently serves as chairman of the board of International School Services, contributing her expertise in finance and governance. Ms. Warren holds a B.S. in biological sciences with a minor in neurology from the University of Alberta.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT® (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system without the adverse effects of broad systemic immune modulation. CUE-401, the company’s lead autoimmune asset, is designed to act mechanistically both as a regulator of proinflammatory mechanisms, and as a master switch for regulatory T cell (Treg) differentiation to induce tolerance. It is a highly innovative, tolerogenic bifunctional molecule combining a TGF-beta breathing-mask moiety with Cue Biopharma’s clinically validated interleukin 2 (IL-2) mutein in a single injectable biologic.
Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company’s belief regarding the potential benefits and applications of its drug candidates and programs, including the company’s plans to further advance its differentiating Immuno-STAT® platform and lead autoimmune asset, CUE-401, including the company’s plans to move CUE-401 into the clinic by the second half of 2026; and the company’s business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “promise” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s ability to maintain its collaboration with ImmunoScape; the company’s limited operating history, limited cash and a history of losses; the company’s ability to obtain adequate financing to fund its business operations in the near term and successfully remediate its current “going concern” determination that it does not have sufficient capital on hand to continue operations beyond the next twelve months; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the company’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required U.S. Food and Drug Administration (FDA) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the company’s operations and clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to obtain adequate financing to fund its business operations in the future and ability to continue as a going concern; the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
FAQ
Who is the interim CEO of Cue Biopharma (CUE) as of March 27, 2026?
Why did Cue Biopharma (CUE) name Lucinda Warren interim CEO on March 27, 2026?
What is Cue Biopharma's timeline for CUE-401 after the March 27, 2026 leadership change?
What recent deals did Cue Biopharma announce alongside the March 27, 2026 CEO change?
How might the March 26–27, 2026 executive changes affect Cue Biopharma (CUE) operations?
